These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 8979141)

  • 1. New antithrombotic agents for the prevention and treatment of deep vein thrombosis.
    Boneu B
    Haemostasis; 1996 Oct; 26 Suppl 4():368-78. PubMed ID: 8979141
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heparin, low-molecular-weight heparins, and heparin pentasaccharide: basic and clinical differentiation.
    Hoppensteadt D; Walenga JM; Fareed J; Bick RL
    Hematol Oncol Clin North Am; 2003 Feb; 17(1):313-41. PubMed ID: 12627673
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Danaparoid sodium.
    Acostamadiedo JM; Iyer UG; Owen J
    Expert Opin Pharmacother; 2000 May; 1(4):803-14. PubMed ID: 11249517
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modern aspects of prophylaxis and therapy for venous thrombo-embolic disease.
    Bergqvist D
    Aust N Z J Surg; 1998 Jul; 68(7):463-8. PubMed ID: 9669358
    [No Abstract]   [Full Text] [Related]  

  • 5. Factor Xa inhibitors: new anti-thrombotic agents and their characteristics.
    Ieko M; Tarumi T; Nakabayashi T; Yoshida M; Naito S; Koike T
    Front Biosci; 2006 Jan; 11():232-48. PubMed ID: 16146728
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ardeparin and danaparoid for prevention of deep vein thrombosis.
    Med Lett Drugs Ther; 1997 Oct; 39(1011):94-5. PubMed ID: 9379998
    [No Abstract]   [Full Text] [Related]  

  • 7. Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
    Garcia DA; Baglin TP; Weitz JI; Samama MM
    Chest; 2012 Feb; 141(2 Suppl):e24S-e43S. PubMed ID: 22315264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glycosaminoglycans: clinical use.
    Boneu B
    Semin Thromb Hemost; 1996; 22(2):209-12. PubMed ID: 8807719
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of thrombotic and cardiovascular disorders in the new millenium.
    Fareed J; Hoppensteadt DA; Bick RL
    Clin Appl Thromb Hemost; 2003 Apr; 9(2):101-8. PubMed ID: 12812377
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Orgaran (Org 10172): its pharmacological profile in experimental models.
    Meuleman DG
    Haemostasis; 1992; 22(2):58-65. PubMed ID: 1379965
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Orgaran in the prevention of deep vein thrombosis in stroke patients.
    Turpie AG
    Haemostasis; 1992; 22(2):92-8. PubMed ID: 1379969
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New therapeutic options in DVT prophylaxis.
    Wille-Jørgensen P
    Orthopedics; 2000 Jun; 23(6 Suppl):s639-42. PubMed ID: 10875428
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A fixed-dose combination of low molecular weight heparin with dihydroergotamine versus adjusted-dose unfractionated heparin in the prevention of deep-vein thrombosis after total hip replacement.
    Horbach T; Wolf H; Michaelis HC; Wagner W; Hoffmann A; Schmidt A; Beck H
    Thromb Haemost; 1996 Feb; 75(2):246-50. PubMed ID: 8815569
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Anticoagulant therapy in pulmonary embolism].
    Charbonnier B; Pacouret G; Augusseau-Richard MP; Dessenne X; Pagot O
    Arch Mal Coeur Vaiss; 1995 Nov; 88(11 Suppl):1755-61. PubMed ID: 8815836
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The present and future of heparin, low molecular weight heparins, pentasaccharide, and hirudin for venous thromboembolism and acute coronary syndromes.
    Haas S
    Semin Vasc Med; 2003 May; 3(2):139-46. PubMed ID: 15199477
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An update on heparins at the beginning of the new millennium.
    Fareed J; Hoppensteadt DA; Bick RL
    Semin Thromb Hemost; 2000; 26 Suppl 1():5-21. PubMed ID: 11011802
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low-molecular-weight heparins or heparinoids versus standard unfractionated heparin for acute ischemic stroke (Cochrane review).
    Counsell C; Sandercock P
    Stroke; 2002 Jul; 33(7):1925-6. PubMed ID: 12105377
    [No Abstract]   [Full Text] [Related]  

  • 18. Danaparoid in the prevention of thromboembolic complications.
    Skoutakis VA
    Ann Pharmacother; 1997; 31(7-8):876-87. PubMed ID: 9220051
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Treatment and prophylaxis of deep venous thrombosis with low molecular weight heparins (meta-analysis of clinical trials)].
    Valiukiene L; Naudziūnas A; Unikauskas A
    Medicina (Kaunas); 2003; 39(4):352-8. PubMed ID: 12738903
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synopsis of the anticoagulant and antithrombotic profile of the low molecular weight heparinoid Org 10172 in experimental models.
    Meuleman DG
    Semin Thromb Hemost; 1989 Oct; 15(4):370-2. PubMed ID: 2479103
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.